Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34287
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDjajawi, Tirta Mario-
dc.contributor.authorWichmann, Johannes-
dc.contributor.authorVervoort, Stephin J-
dc.contributor.authorKearney, Conor J-
dc.date2023-
dc.date.accessioned2023-12-01T00:37:40Z-
dc.date.available2023-12-01T00:37:40Z-
dc.date.issued2023-11-16-
dc.identifier.citationThe FEBS Journal 2023-11-16en_US
dc.identifier.issn1742-4658-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34287-
dc.description.abstractDespite the clinical success of cancer immunotherapies including immune checkpoint blockade and adoptive cellular therapies across a variety of cancer types, many patients do not respond or ultimately relapse; however, the molecular underpinnings of this are not fully understood. Thus, a system-level understating of the routes to tumor immune evasion is required to inform the design of the next generation of immunotherapy approaches. CRISPR screening approaches have proved extremely powerful in identifying genes that promote tumor immune evasion or sensitize tumor cells to destruction by the immune system. These large-scale efforts have brought to light decades worth of fundamental immunology and have uncovered the key immune-evasion pathways subverted in cancers in an acquired manner in patients receiving immune-modulatory therapies. The comprehensive discovery of the main pathways involved in immune evasion has spurred the development and application of novel immune therapies to target this process. Although successful, conventional CRISPR screening approaches are hampered by a number of limitations, which obfuscate a complete understanding of the precise molecular regulation of immune evasion in cancer. Here, we provide a perspective on screening approaches to interrogate tumor-lymphocyte interactions and their limitations, and discuss further development of technologies to improve such approaches and discovery capability.en_US
dc.language.isoeng-
dc.subjectCRISPRen_US
dc.subjectimmune evasionen_US
dc.subjectlymphocytesen_US
dc.subjectscreeningen_US
dc.subjecttechnologyen_US
dc.titleTumor immune evasion: insights from CRISPR screens and future directions.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe FEBS Journalen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research, Parkville, Vic., Australia.en_US
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Vic., Australia.en_US
dc.identifier.doi10.1111/febs.17003en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-9891-5078en_US
dc.identifier.pubmedid37971319-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Jul 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.